摘要:
The present invention relates to antagonists of neuropilin receptor fuction and use thereof in the treatment of cancer, particularly metastatic cancer, and angiogenic diseases.
摘要:
The present invention relates to antagonists of neuropilin receptor fuction and use thereof in the treatment of cancer, particularly metastatic cancer, and angiogenic diseases.
摘要:
The present invention relates to antagonists of neuropilin receptor function and use thereof in the treatment of cancer particularly, metastatic cancer and angiogenic diseases.
摘要:
The present invention relates to antagonists of neuropilin receptor function and use thereof in the treatment of cancer, particularly metastatic cancer, and angiogenic diseases.
摘要:
The present invention relates to antagonists of neuropilin receptor function and use thereof in the treatment of cancer, particularly metastatic cancer, and angiogenic diseases.
摘要:
The present invention relates to VEGF receptors (VEGFR) and neuropilins such as VEGF165R/NP-1 and NP-2 that are associated with metastatic potential of a malignant cell and their use in the diagnosis and prognosis of cancer. Preferred ones are VEGF165R/NP-1 and NP-2 but any neuropilin or VEGFR, where the constituents share at least about 85% homology with either of the above VEGF165R/NP-1 and NP-2 can be used. More preferably, such constituent shares at least 90% homology. Still more preferably, each constituent shares at least 95% homology.
摘要:
The present invention provides isolated polypeptides having VEGF antagonist activity, pharmaceutical compositions and methods of treatment. The polypeptides of the invention include polypeptides comprising a portion of SEQ ID NO: 1 having VEGF antagonist activity, polypeptides comprising SEQ ID NO: 2 or a portion thereof having VEGF antagonist activity, and a polypeptide having the structure of formula (I), set forth above. The present invention further includes analogs and derivatives of these polypeptides having VEGF antagonist activity.
摘要翻译:本发明提供具有VEGF拮抗剂活性的分离的多肽,药物组合物和治疗方法。 本发明的多肽包括包含具有VEGF拮抗剂活性的SEQ ID NO:1的一部分的多肽,包含SEQ ID NO:2的多肽或其具有VEGF拮抗剂活性的部分,以及具有式(I)结构的多肽, 以上。 本发明还包括具有VEGF拮抗剂活性的这些多肽的类似物和衍生物。
摘要:
The present invention relates to cDNA encoding a soluble neuropilin protein (sNP) which is isolated from neuropilin (NP) producing cells or is recombinantly engineered from NP-encoding DNA. NP-1 and NP-2 are preferred NPs but any neuropilin or VEGF receptor (VEGFR), where the constituents share at least about 85% homology with either of the above VEGF165R/NP-1 and NP-2. More preferably, such constituent shares at least 90% homology. Still more preferably, each constituent shares at least 95% homology.
摘要:
The present invention provides isolated polypeptides having VEGF antagonist activity, pharmaceutical compositions and methods of treatment of subjects having a disease or disorder associated with VEGF activity or subjects having tumors expressing a VEGF receptor. The polypeptides of the invention include polypeptides comprising a portion of SEQ ID NO: 1 having VEGF antagonist activity, polypeptides comprising SEQ ID NO: 2 or a portion thereof having VEGF antagonist activity, and a polypeptide having the structure of formula (I), set forth above. The present invention further includes analogs and derivatives of these polypeptides having VEGF antagonist activity.
摘要翻译:本发明提供具有VEGF拮抗剂活性的分离的多肽,药物组合物和治疗患有VEGF活性相关疾病或病症的受试者或具有表达VEGF受体的肿瘤的受试者的方法。 本发明的多肽包括包含具有VEGF拮抗剂活性的SEQ ID NO:1的一部分的多肽,包含SEQ ID NO:2的多肽或其具有VEGF拮抗剂活性的部分,以及具有式(I)结构的多肽, 以上。 本发明还包括具有VEGF拮抗剂活性的这些多肽的类似物和衍生物。
摘要:
The present invention relates to cDNA encoding a soluble neuropilin protein (sNP) which is isolated from neuropilin (NP) producing cells or is recombinantly engineered from NP-encoding DNA. NP-1 and NP-2 are preferred NPs but any neuropilin or VEGF receptor (VEGFR), where the constituents share at least about 85% homology with either of the above VEGF165R/NP-1 and NP-2. More preferably, such constituent shares at least 90% homology. Still more preferably, each constituent shares at least 95% homology.
摘要翻译:本发明涉及编码可溶性神经蛋白蛋白(sNP)的cDNA,其从产生神经纤维蛋白(NP)的细胞中分离或从NP编码DNA重组工程改造。 NP-1和NP-2是优选的NP,但是任何神经纤维蛋白或VEGF受体(VEGFR),其中组分与上述VEGF 165 R / NP-1中的任一个具有至少约85%的同源性, NP-2。 更优选地,这样的成分具有至少90%的同源性。 更优选地,每个成分具有至少95%的同源性。